Working… Menu
Trial record 1 of 1 for:    NCT03195699
Previous Study | Return to List | Next Study

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03195699
Recruitment Status : Recruiting
First Posted : June 22, 2017
Last Update Posted : May 26, 2021
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Tvardi Therapeutics, Incorporated

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021